# Apple Faces $634 Million Patent Infringement Verdict in Masimo Case
In a significant blow to tech giant Apple, a California federal jury has ruled that the company must pay medical technology firm Masimo $634 million for patent infringement related to Apple Watch health features[1][4]. The verdict, announced on November 14, 2025, marks another chapter in an ongoing legal battle between the two companies over intellectual property rights in the wearable health technology space.
## The Verdict and Patent in Question
The jury’s decision came after an eight-day trial in the U.S. District Court for the Central District of California[1]. The case centered on Masimo Patent No. 10,433,776, which covers pulse oximetry technology—specifically blood-oxygen reading capabilities[2]. The jury determined that certain Apple Watch features, including workout mode and heart rate notification functionality, violated Masimo’s patent rights[4].
This represents a substantial financial penalty for Apple and underscores the importance of patent protection in the competitive health technology sector. The $634 million award reflects the jury’s assessment of damages resulting from the infringement[1].
## The Technology at the Heart of the Dispute
The patent in question covers technology that monitors blood oxygen levels and alerts users about abnormal heart rates[1]. These health monitoring capabilities have become increasingly central to modern smartwatches, making the technology particularly valuable in the wearable device market. Masimo, a company specializing in medical-monitoring technology, developed this innovation and sought to protect its intellectual property rights through litigation[4].
Apple integrated similar functionality into its Apple Watch line, which Masimo argued constituted patent infringement. The jury agreed with Masimo’s position, finding that Apple’s implementation of workout mode and heart rate notification features relied on technology protected by Masimo’s patent[4].
## Apple’s Response and Appeal Plans
Apple has made clear its disagreement with the verdict and intends to pursue an appeal[4]. An Apple spokesperson stated that the company believes the patent in question expired in 2022 and is “specific to historic patient monitoring technology from decades ago”[4][7]. This argument suggests Apple views the patent as outdated and questions the relevance of the technology to current Apple Watch features.
Additionally, Apple has pointed out that Masimo has pursued an extensive litigation strategy against the company. According to Apple’s statement, over the past six years, Masimo has “sued Apple in multiple courts and asserted over 25 patents, the majority of which have been found to be invalid”[4]. This context suggests Apple views the current verdict as part of a broader pattern of litigation rather than a definitive determination of wrongdoing.
## A Multi-Front Legal Battle
This California verdict represents just one aspect of a larger, contentious patent dispute between the two companies. The litigation spans multiple jurisdictions and involves numerous patents, creating a complex legal landscape[4]. Beyond the patent infringement case, Masimo has also accused Apple of hiring away its employees and stealing its pulse oximetry technology for use in Apple Watches[4].
The International Trade Commission has also been involved in this dispute. In October 2023, the ITC ruled in favor of Masimo and issued an exclusion order prohibiting Apple from importing devices with the Blood Oxygen Wellness app into the United States[6]. However, the ITC has since decided to hold a new proceeding to determine whether Apple’s updated watches should remain subject to the ban[4].
The legal complexity extends further, with a California judge declaring a mistrial in Masimo’s trade-secret case against Apple in 2023 after a jury failed to reach a unanimous verdict[4]. Meanwhile, Apple has also pursued its own litigation against Masimo, winning a minimal $250 verdict in Delaware last year over allegations that Masimo’s smartwatches infringe two Apple design patents[4].
## Industry Implications
The $634 million verdict carries significant implications for the technology and health monitoring industries. It highlights the importance of conducting thorough patent research and ensuring compliance with existing intellectual property protections[1]. For companies developing wearable health devices, the case demonstrates that patent infringement in this space can result in substantial financial penalties.
The verdict also underscores the value that courts place on health technology innovations. As wearable devices become increasingly sophisticated and health-focused, companies must navigate a complex landscape of existing patents and intellectual property claims[1].
## Masimo’s Position
Masimo has characterized the verdict as a significant victory in its efforts to protect its innovations and intellectual property. The company emphasized its commitment to developing technologies that benefit patients and protecting its intellectual property rights[6]. For Masimo, the verdict validates its position that Apple infringed on its patented technology and represents a meaningful recognition of the company’s innovation in medical monitoring.
## Looking Ahead
As Apple prepares its appeal, the case will likely continue to generate legal and industry attention. The outcome could have implications for how companies approach health technology development in wearable devices and the importance of patent clearance in product development[1].
The verdict serves as a reminder that even the world’s most valuable companies are not immune to patent infringement claims. Whether Apple’s appeal succeeds or the verdict stands, this case will remain a significant landmark in the intersection of intellectual property law and health technology innovation.
Original source: TechCrunch – Jury says Apple owes Masimo $634M for patent infringement